Skip to main content
诺思兰德 logo

诺思兰德 — Investor Relations & Filings

Ticker · 920047 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 539 across all filing types
Latest filing 2023-11-28 Governance Information
Country CN China
Listing Beijing Stock Exchange 920047

About 诺思兰德

https://www.northland-bio.com/

Northland Biotech focuses on the research, development, and commercialization of gene therapies and recombinant protein pharmaceuticals. The company’s primary therapeutic areas include cardiovascular diseases, peripheral arterial diseases, and ophthalmology. Its core R&D pipeline features NL003, a hepatocyte growth factor gene therapy targeting critical limb ischemia, and NL005, a recombinant human thymosin beta 4 for treating myocardial ischemia. Beyond its innovative pipeline, the company maintains advanced manufacturing facilities for biologics and ophthalmic preparations, producing a range of specialized eye drops. By leveraging its proprietary technology platforms, Northland Biotech aims to provide effective treatments for chronic and degenerative conditions through advanced molecular medicine.

Recent filings

Filing Released Lang Actions
独立董事工作制度
Governance Information Classification · 100% confidence The document is titled "北京诺思兰德生物技术股份有限公司独立董事工作制度" which translates to "Beijing Northland Biotechnology Co., Ltd. Independent Director Work System." It details the rules, responsibilities, nomination, election, and working conditions of independent directors in the company. It references relevant laws, regulations, and stock exchange rules, and is dated November 29, 2023. The content is a governance framework document rather than a financial report, earnings release, or announcement of voting results. It is not a proxy solicitation or remuneration report. It is a governance-related document outlining internal rules and board structure related to independent directors. Therefore, the most appropriate classification is Governance Information (CGR). The document length is substantial (9941 characters), indicating it is the full text of the governance document, not just an announcement or summary.
2023-11-28 Chinese
董事会审计委员会工作细则
Governance Information Classification · 95% confidence The document is titled as the 'Audit Committee Work Rules' of Beijing Northland Biotechnology Co., Ltd., detailing the composition, responsibilities, procedures, and authority of the audit committee. It is a governance-related document outlining internal rules and structures related to audit oversight. There is no financial data, no report of financial results, no announcement of voting results, no earnings data, and no indication of a report publication or regulatory filing. The document is a detailed governance framework for the audit committee, which fits the definition of Governance Information (CGR). The document length is 3701 characters, which is relatively short but contains substantive governance content, not just an announcement or certification. Therefore, the best classification is CGR with high confidence.
2023-11-28 Chinese
关联交易管理制度
Governance Information Classification · 95% confidence The document is titled as a management system for related party transactions of Beijing Northland Biotechnology Co., Ltd. It details the company's internal rules and procedures for managing related party transactions, including definitions, principles, approval processes, disclosure requirements, and exceptions. It is a governance-related document focusing on internal control and compliance with laws and stock exchange rules. There is no financial data, no audit or financial report, no announcement of voting results, no earnings data, no capital or financing update, no legal proceedings, no merger or acquisition information, and no shareholder transaction. The document is a detailed governance policy document, which fits the Governance Information (CGR) category best.
2023-11-28 Chinese
第六届监事会第六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolution passed at the sixth meeting of the sixth supervisory board of Beijing Northland Biotechnology Co., Ltd. It details the meeting's time, location, attendance, agenda, and voting results regarding the proposed amendment of the company's articles of association. It references regulatory compliance with the China Securities Regulatory Commission and the Beijing Stock Exchange rules. The document is an official announcement of a board/supervisory meeting decision and does not contain financial statements, audit results, or detailed financial data. It is not a full report, earnings release, or presentation. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by company boards or senior management bodies.
2023-11-28 Chinese
投资者关系活动记录表
Investor Presentation Classification · 95% confidence The document is titled as an "投资者关系活动记录表" which translates to "Investor Relations Activity Record." It details a recent investor relations event held by the company, including the format (onsite and online), participants (various funds and securities firms), company representatives, and a Q&A session about the company's drug NL003. The content focuses on investor communication and engagement rather than financial results, regulatory filings, or formal reports. The document length is short (1970 characters), and it is clearly a record of an investor relations activity rather than a financial report or announcement. Therefore, the document best fits the category of Investor Presentation (IP), as it is a detailed presentation for investors focusing on company products, strategy, and development progress.
2023-11-26 Chinese
关于NL003项目III期临床试验静息痛适应症完成300例受试者入组预设目标的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the completion of enrollment of 300 subjects in a Phase III clinical trial for a drug candidate. It includes details about the clinical trial progress, impact on financials, and risk warnings. There are no financial statements, no detailed financial performance data, and no regulatory form references. The document is short (1068 characters) and serves as an update on a clinical trial milestone rather than a financial report or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is an announcement of a clinical trial progress milestone, which is best categorized under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2023-11-26 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.